ДИСТИРЕОИДНАЯ ОПТИЧЕСКАЯ НЕЙРОПАТИЯ
Ключевые слова:
Дистиреоидная оптическая нейропатия, эндокринная офтальмопатия, эпидемиология, факторы рискаАннотация
Эндокринная офтальмопатия — это аутоиммунное заболевание, часто связанное с нарушениями функции щитовидной железы. Оно поражает ткани орбиты и периорбитальные структуры, вызывая их отек и дегенеративные изменения. Одним из наиболее серьезных осложнений эндокринной офтальмопатии является дистиреоидная оптическая нейропатия (ДОН) — патология, при которой страдает зрительный нерв. ДОН является сравнительно новым и активно изучаемым состоянием, которое может привести к необратимой утрате зрения.
Библиографические ссылки
Bartalena L, Wiersinga WM, Pinchera A. Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004;27:295–301
Blandford AD, Zhang D, Chundury RV, Perry JD. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol. 2017;12(2):111-121. https://doi.org/10.1080/17469899.2017.1276444.
Brown, C., & Miller, D. (2021). Gender Differences in Eye Diseases. Ophthalmology Research, 45(3), 213-220.
Chan Jeon 1, Jae Ho Shin, Kyung In Woo, Yoon-Duck Kim Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy PMID: 22511831 PMCID: PMC3325624 DOI: 10.3341/kjo.2012.26.2.73
Giaconi JA, Kazim M, Rho T, Pfaff C. CT scan evidence of dysthyroid optic neuropathy. Ophthalmic Plast Reconstr Surg. 2002 May;18(3):177-82
Huang, X., & Li, Z. (2021). "Geographic Variability in Thyroid Eye Disease Incidence." International Journal of Epidemiology, 50(5), 1547-1555.
Jang SY, Lee SY, Lee EJ, Yoon JS. Клинические особенности тиреоидной офтальмопатии у клинически эутиреоидных корейских пациентов. Eye (Lond) 2012; 26 :1263–1269. doi: 10.1038/eye.2012.132
Ji X, Xiao W, Ye H, Chen R, Wu J, Mao Y, Yang H.Eye (Lond). 2021 Feb;35(2):568-574. doi: 10.1038/s41433-020-0904-2. Epub 2020 Apr 30.PMID: 32355235
Jones, L., & White, C. (2019). The Impact of Thyroid-Related Eye Disease on Quality of Life. British Journal of Ophthalmology, 103(11), 1527-1533.
Jwu Jin Khong 1, Sue Finch 1, Chamika De Silva 1, Stacey Rylander 1, Jamie E Craig 1, Dinesh Selva 1, Peter R EbelingRisk Factors for Graves' Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study PMID: 27055083 DOI: 10.1210/jc.2015-4294
Kazim M, Trokel SL, Acaroglu G, Elliott A. Reversal of dysthyroid optic neuropathy following orbital fat decompression. Br J Ophthalmol. 2000 Jun;84(6):600-5.
Lazarus J.H. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012; 26:273–279
Kitaguchi Y, Ishihara K, Nishida K. Spontaneous resolution of euthyroid optic neuropathy. Can J Ophthalmol. 2019;54:e188–e192. doi: 10.1016/j.jcjo.2018.10.014.
Lee YC, Chang FL, Tsai RK. Intravenous pulse corticosteroid therapy in euthyroid optic neuropathy: A case report. Neuro Ophthalmol. 2012;36:143–145.
L Bartalena , P E Macchia , C Marcocci , M Salvi , F Vermiglio Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement PMID: 25722226 PMCID: PMC4374116 DOI: 10.1007/s40618-015-0257-z
Mioara-Laura Macovei, Űnal Azis, Alina Gabriela Gheorghe, Marian Burcea A systematic review of euthyroid Graves' disease (Review) 2021 Nov;22(5):1346. doi: 10.3892/etm.2021.10781. Epub 2021 Sep 22.
Miśkiewicz P, Rutkowska B, Jabłońska A, Krzeski A, Trautsolt-Jeziorska K, Kęcik D, Milczarek-Banach J, Pirko-Kotela K, Samsel A, Bednarczuk T. Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy. Endokrynol Pol. 2016;67(2):166-73.
Nisar Sonam Poonam, Md. Shahid Alam, Prashant Oberoi, Bipasha Mukherjee Indian J Ophthalmol. Dysthyroid optic neuropathy: Demographics, risk factors, investigations, and management outcomes 2022 Dec; 70(12): 4419–4426. Published online 2022 Nov 30. doi: 10.4103/ijo.IJO_719_22 PMCID: PMC9940533
Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol. 2003;148:491–495.
R Kalmann 1, M P Mourits Diabetes mellitus: a risk factor in patients with Graves' orbitopathy PMID: 10434871 PMCID: PMC1723016 DOI: 10.1136/bjo.83.4.463
Сидоров С.Н. "Дистиреоидная оптическая нейропатия: клинический случай и обзор литературы". Офтальмологический журнал, 2020.
Smith, J., Green, H., & Miller, T. (2018). Smoking and Its Impact on Optic Neuropathy. Journal of Ophthalmology, 45(2), 120-130.
Soni CR, Johnson LN. Visual neuropraxia and progressive vision loss from thyroid-associated stretch optic neuropathy. Eur J Ophthalmol. 2010 Mar-Apr;20(2):429-36
Termote K, Decallonne B, Mombaerts I. The influence of prior hyperthyroidism on euthyroid graves' ophthalmopathy. J Ophthalmol. 2014;2014(426898) doi: 10.1155/2014/426898.
Thompson, K. & Martinez, L. Thyroid Disorders. (2020). (2022). The effects of pregnancy on thyroid health. Obstetrics & Gynecology Research, 49(2), 100-107
Walkelkamp MJ, Badelschit L, Saeedt P, Mouritd MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as first-line treatment of optic neuropathy in Graves’ ophthalmopathy a randomized controlled trial. Clin Endocrinol. 2005; 63: 323–28.
Yun Wong, Jane Dickinson, Petros Perros, Colin Dayan, Pratibha Veeramani, Daniel Morris, Barny Foot, Lucy Clarke Eye (Lond) A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom 2018 Oct; 32(10): 1555–1562. Published online 2018 Jun 18. doi: 10.1038/s41433-018-0144-x PMCID: PMC6189132].
Yuji Hiromatsu 1, Hiroyuki Eguchi, Junichi Tani, Masataka Kasaoka, Yasuo TeshimaGraves' ophthalmopathy: epidemiology and natural history MID: 24583420 DOI: 10.2169/internalmedicine.53.1518.
